# Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

> **NCT00032292** · PHASE1,PHASE2 · COMPLETED · sponsor: **Facet Biotech** · enrollment: 34 (—)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Visilizumab

## Key facts

- **NCT ID:** NCT00032292
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 34 (—)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032292, "Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00032292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*